Khanam Saima, Etemad Behzad, Khanna Navin, Swaminathan Sathyamangalam
International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
Am J Trop Med Hyg. 2006 Feb;74(2):266-77.
There is no vaccine to prevent dengue fever, a mosquito-borne viral disease, caused by four serotypes of dengue viruses. In this study, which has been prompted by the emergence of dengue virus envelope domain III as a promising sub-unit vaccine candidate, we have examined the possibility of developing a chimeric bivalent antigen with the potential to elicit neutralizing antibodies against two serotypes simultaneously. We created a chimeric dengue antigen by splicing envelope domain IIIs of serotypes 2 and 4. It was expressed in Escherichia coli and purified to near homogeneity. This protein retains the antigenic identities of both its precursors. It elicited antibodies that could efficiently block host cell binding of both serotypes 2 and 4 of dengue virus and neutralize their infectivity (neutralizing antibody titers approximately 1:40 and ~1:80 for dengue virus serotypes 2 and 4, respectively). This work could be a forerunner to the development of a single envelope domain III-based tetravalent antigen.
目前尚无预防登革热的疫苗，登革热是一种由四种血清型登革病毒引起的蚊媒病毒性疾病。在这项因登革病毒包膜结构域III成为有前景的亚单位疫苗候选物而开展的研究中，我们研究了开发一种嵌合二价抗原的可能性，该抗原具有同时引发针对两种血清型的中和抗体的潜力。我们通过拼接血清型2和4的包膜结构域III创建了一种嵌合登革热抗原。它在大肠杆菌中表达并纯化至接近均一。该蛋白保留了其两种前体的抗原特性。它引发的抗体能够有效阻断登革病毒血清型2和4与宿主细胞的结合，并中和它们的感染性（登革病毒血清型2和4的中和抗体滴度分别约为1:40和~1:80）。这项工作可能是开发基于单个包膜结构域III的四价抗原的先驱。
